Adapt Pharma touted data today from 2 human factors studies that evaluated the usability of its Narcan nasal spray by adolescents and people with low literacy.
The Dublin-based company’s product is a ready-to-use, needle-free device that delivers a single dose of naloxone in a nasal spray to someone experiencing an opioid overdose and does not require assembly prior to use, according to Adapt Pharma.
The human factors data were presented at the annual International Conference on Opioids.
Adapt Pharma found that without instruction or training, adults and kids can properly deploy Narcan in a simulated emergency situation.
“The study demonstrated that ready-to-use, intranasal naloxone can be used by a layperson to administer this drug to those experiencing an opioid-related overdose,” lead author Melissa Beck said in prepared remarks.
“As the opioid epidemic evolves, we are seeing a growing need to prepare and equip all populations with tools to help their loved ones, neighbors and community members,” Adapt Pharma’s president of U.S. operations, Mike Kelly, added. “This study offers additional insight into how community members can utilize Narcan nasal spray for the treatment of a known or suspected opioid overdose while waiting for emergency help to arrive.”
